Tobin Schilke - Dec 15, 2022 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Dec 15, 2022
Transactions value $
-$33,476
Form type
4
Date filed
12/16/2022, 03:12 PM
Previous filing
Mar 9, 2023
Next filing
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability -$33.5K -1.56K -2.45% $21.50 61.9K Dec 15, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 4,500 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.